AtriCure, Inc. provided earnings guidance for 2023. For the period, Management projects revenue of approximately $380 million to $387 million, reflecting growth of approximately 15% to 17% over full year 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.3 USD | +6.39% |
|
+13.76% | -29.11% |
01/07 | AtriCure, Inc.(NasdaqGM:ATRC) dropped from Russell 2000 Value-Defensive Index | CI |
01/07 | AtriCure, Inc.(NasdaqGM:ATRC) dropped from Russell 2000 Growth-Defensive Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.11% | 1.22B | |
-6.68% | 179B | |
-5.20% | 100B | |
-5.38% | 66.67B | |
+18.16% | 44.81B | |
-6.47% | 46.16B | |
+9.74% | 44.38B | |
+14.01% | 29.53B | |
+22.31% | 25.83B | |
-6.53% | 23.97B |
- Stock Market
- Equities
- ATRC Stock
- News AtriCure, Inc.
- AtriCure, Inc. Provides Earnings Guidance for 2023